Literature DB >> 16394033

Relation between increased fetal nuchal translucency thickness and chromosomal defects.

Karl Oliver Kagan1, Kyriaki Avgidou, Francisca S Molina, Katarzyna Gajewska, Kypros H Nicolaides.   

Abstract

OBJECTIVE: To examine the prevalence and distribution of all chromosomal defects in fetuses with increased nuchal translucency thickness.
METHODS: Assessment of risk for trisomy 21 was carried out by a combination of maternal age and fetal nuchal translucency thickness at 11-13 + 6 weeks. A search of the database was made to identify, first, all singleton pregnancies in which fetal karyotyping was carried out and, second, the cases where the fetal nuchal translucency was equal to or above the 95th centile for fetal crown-rump length. The prevalence and distribution of chromosomal defects were determined for each nuchal translucency category: between the 95th centile for crown-rump length and 3.4 mm, 3.5-4.4 mm, 4.5-5.4 mm, 5.5-6.4 mm, 6.5-7.4 mm, 7.5-8.4 mm, 8.5-9.4 mm, 9.5-10.4 mm, 10.5-11.4 mm, and 11.5 mm or more.
RESULTS: The search identified 11,315 pregnancies. The median maternal age was 34.5 (range 15-50) years, and the median fetal crown-rump length was 64 (range 45-84) mm. The fetal karyotype was abnormal in 2,168 (19.2%) pregnancies, and the incidence of chromosomal defects increased with nuchal translucency thickness from approximately 7% for those with nuchal translucency between the 95th centile for crown-rump length and 3.4 mm to 75% for nuchal translucency of 8.5 mm or more. In the majority of fetuses with trisomy 21, the nuchal translucency thickness was less then 4.5 mm, whereas in the majority of fetuses with trisomies 13 or 18 it was 4.5-8.4 mm, and in those with Turner syndrome it was 8.5 mm or more.
CONCLUSION: In fetuses with increased nuchal translucency, approximately one half of the chromosomally abnormal group is affected by defects other than trisomy 21. The distribution of nuchal translucency is different for each type of chromosomal defect. LEVEL OF EVIDENCE: II-3.

Entities:  

Mesh:

Year:  2006        PMID: 16394033     DOI: 10.1097/01.AOG.0000191301.63871.c6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  26 in total

1.  Does increased nuchal translucency indicate a fetal abnormality? A retrospective study to clarify the clinical significance of nuchal translucency in Japan.

Authors:  Shigo Yoshida; Kiyonori Miura; Kentaro Yamasaki; Shoko Miura; Takako Shimada; Terumi Tanigawa; Atsushi Yoshida; Daisuke Nakayama; Hideaki Masuzaki
Journal:  J Hum Genet       Date:  2008-05-24       Impact factor: 3.172

2.  Significance of septa in first trimester increased nuchal translucency thickness.

Authors:  Aytul Corbacioglu Esmer; Ibrahim Kalelioglu; Betul Keyif; Mehmet Ozsurmeli; Atıl Yüksel; Recep Has
Journal:  J Med Ultrason (2001)       Date:  2013-06-19       Impact factor: 1.314

Review 3.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 5.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

6.  SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy.

Authors:  Carole Samango-Sprouse; Milena Banjevic; Allison Ryan; Styrmir Sigurjonsson; Bernhard Zimmermann; Matthew Hill; Megan P Hall; Margaret Westemeyer; Jennifer Saucier; Zachary Demko; Matthew Rabinowitz
Journal:  Prenat Diagn       Date:  2013-06-20       Impact factor: 3.050

7.  Prenatal diagnosis of common aneuploidies in transcervical samples using quantitative fluorescent-PCR analysis.

Authors:  Cecilia Bussani; Riccardo Cioni; Alberto Mattei; Massimiliano Fambrini; Mauro Marchionni; Gianfranco Scarselli
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening.

Authors:  Victoria K Berger; Mary E Norton; Teresa N Sparks; Monica Flessel; Rebecca J Baer; Robert J Currier
Journal:  Prenat Diagn       Date:  2019-12-02       Impact factor: 3.050

Review 9.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 10.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.